Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.64 |
| ▸ | HPGDS | O60760 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | CFD | P00746 | 1/20 | 0.54 |
| ▸ | CCKBR | P32239 | 1/20 | 0.53 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576509 | 0.89 | ADAMTS5 (0.62) | MMP2EPHX2NR1H4CCKBR | |
| SCHEMBL3591190 | 0.88 | CTSB (0.55) | PADI6HPGDSMMP2CCKBR | |
| SCHEMBL3585812 | 0.87 | PADI6 (0.52) | PADI6HPGDSMMP2CCKBR | |
| SCHEMBL3587165 | 0.86 | MMP2 (0.55) | PADI6MMP2CCKBR | |
| SCHEMBL3584960 | 0.85 | CTSL (0.55) | PADI6MMP2CCKBR | |
| SCHEMBL2247747 | 0.85 | KDM1A (0.53) | MMP2CCKBR | |
| SCHEMBL3579414 | 0.85 | ADAMTS5 (0.57) | MMP2EPHX2NR1H4CCKBR | |
| SCHEMBL2249522 | 0.84 | ADAMTS5 (0.54) | PADI6MMP2NR1H4CCKBR | |
| SCHEMBL2247866 | 0.84 | ADAMTS5 (0.56) | PADI6MMP2EPHX2NR1H4CCKBR | |
| SCHEMBL2247917 | 0.83 | CTSL (0.60) | PADI6MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | PADI6 284/4885HPGDS 1417/4885MMP2 49/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | PADI6 284/4885HPGDS 1417/4885MMP2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.